HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

New heights for NewLimit as anti-aging biotech nabs $435M to rejuvenate old cells

Anti-aging startup NewLimit is back with a fresh fundraise of $435 million after landing on its first clinic-ready candidate years earlier than expected.

By FierceBiotech · Jun 3, 2026 · via FierceBiotech
New heights for NewLimit as anti-aging biotech nabs $435M to rejuvenate old cells

Image: FierceBiotech

This is an aggregated industry headline. Read the full story at FierceBiotech →

Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
Rising Stars: WPP's Meghan O'Hora on the 'complex puzzle' of oncology drug marketing
The WeekFiercePharma ↗
Rising Stars: WPP's Meghan O'Hora on the 'complex puzzle' of oncology drug marketing
For Meghan O'Hora, pharma marketing isn't about patients. It's about people and making real connections that h…
Jun 3, 2026
Cingulate’s FDA Rejection Centers on Manufacturing, Not Safety
The WeekBriefing
Cingulate’s FDA Rejection Centers on Manufacturing, Not Safety
The agency’s Complete Response Letter delays CTx‑1301, the biotech’s first commercial hopeful, over CMC issues…
Jun 3, 2026
Top ultra-processed food researchers call for sweeping policy change: 'The system is rigged'
The WeekSTAT News ↗
Top ultra-processed food researchers call for sweeping policy change: 'The system is rigged'
A survey finds that ultra-processed foods are a cross-partisan concern. And yet policy has been slow to follow…
Jun 3, 2026